News
NICE in draft guidance does not recommend the combination of Keytruda + Inlyta to treat renal cell carcinoma. Merck Inc.+ Pfizer
The National Institute for Health and Care Excellence (NICE) has released a draft guidance rejecting MSD’s Keytruda (pembrolizumab) when used in combination with Pfizer’s Inlyta (axitinib) to treat advanced renal cell carcinoma .
The rejection comes despite notable results from the KEYNOTE-426 study, released in 2019, which showed that Keytruda/Inlyta was associated with improved overall survival (hazard ratio 0.53; 95% CI of 0.38 to 0.74; P = 0.00005) and improved progression-free survival (hazard ratio 0.69; 95% CI of 0.57 to 0.84; p = 0.00014) compared with Pfizer’s Sutent (sunitinib) monotherapy.
However NICE found that there was uncertainty around the long-term benefit. NICE also cited inadequate clinical and cost-effectiveness as reasons for not recommending the combination.
Condition: Renal Cell Carcinoma
Type: drug